Pharma sales grow in double digits in March but Covid-19 overhang continues
₹1.47 trillion, up 2.1%, the data showed.While cardiac care and anti-diabetes drugs had a 6.3% and 0.3% growth in sales respectively, most other segments, barring respiratory drugs, vaccines and anti-malarial drugs, grew 8.5-30.3%, primarily due to the low base from the drop in sales in March last year.Anti-malarial drugs slumped 22% in March on account of high sales of the anti-malarial drug hydroxychloroquine last year, which was seeing robust sales due to its initial repurposing for treatment of covid-19.While the drug showed promise against the novel disease initially, later studies showed the drug instead increased the risk of heart attack for patients while providing no significant benefit against covid-19.Among corporates, all top 20.
United States
|
Cases: 46 252 513
Deaths: 750 423
Recovered: 0
|
India
|
Cases: 34 321 025
Deaths: 459 652
Recovered: 0
|
Brazil
|
Cases: 21 835 785
Deaths: 608 235
Recovered: 0
|
United Kingdom
|
Cases: 9 215 683
Deaths: 141 607
Recovered: 0
|
Russia
|
Cases: 8 494 589
Deaths: 237 619
Recovered: 0
|